<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chen J</submitter><funding>National Institute of Neurological Disorders and Stroke</funding><funding>Hong Kong Research Grants Council HKSAR</funding><funding>BrightFocus Foundation</funding><funding>NINDS NIH HHS</funding><pagination>60</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4991002</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Our previous studies of Alzheimer's disease (AD) suggested that glutamine broadly improves cellular readiness to respond to stress and acts as a neuroprotectant both in vitro and in AD mouse models. We now expand our studies to a second neurodegenerative disease, ataxia-telangiectasia (A-T). Unlike AD, where clinically significant cognitive decline does not typically occur before age 65, A-T symptoms appear in early childhood and are caused exclusively by mutations in the ATM (A-T mutated) gene.&lt;h4>Results&lt;/h4>Genetically ATM-deficient mice and wild type littermates were maintained with or without 4 % glutamine in their drinking water for several weeks. In ATM mutants, glutamine supplementation restored serum glutamine and glucose levels and reduced body weight loss. Los</pubmed_abstract><journal>Molecular neurodegeneration</journal><pubmed_title>The impact of glutamine supplementation on the symptoms of ataxia-telangiectasia: a preclinical assessment.</pubmed_title><pmcid>PMC4991002</pmcid><funding_grant_id>GRF660813</funding_grant_id><funding_grant_id>R01 NS071022</funding_grant_id><funding_grant_id>1R01NS071022</funding_grant_id><funding_grant_id>AD2012101</funding_grant_id><pubmed_authors>Hart RP</pubmed_authors><pubmed_authors>Li J</pubmed_authors><pubmed_authors>Chen J</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Chow H</pubmed_authors><pubmed_authors>Plummer MR</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Vail G</pubmed_authors><pubmed_authors>Herrup K</pubmed_authors><pubmed_authors>Louie L</pubmed_authors></additional><is_claimable>false</is_claimable><name>The impact of glutamine supplementation on the symptoms of ataxia-telangiectasia: a preclinical assessment.</name><description>&lt;h4>Background&lt;/h4>Our previous studies of Alzheimer's disease (AD) suggested that glutamine broadly improves cellular readiness to respond to stress and acts as a neuroprotectant both in vitro and in AD mouse models. We now expand our studies to a second neurodegenerative disease, ataxia-telangiectasia (A-T). Unlike AD, where clinically significant cognitive decline does not typically occur before age 65, A-T symptoms appear in early childhood and are caused exclusively by mutations in the ATM (A-T mutated) gene.&lt;h4>Results&lt;/h4>Genetically ATM-deficient mice and wild type littermates were maintained with or without 4 % glutamine in their drinking water for several weeks. In ATM mutants, glutamine supplementation restored serum glutamine and glucose levels and reduced body weight loss. Los</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Aug</publication><modification>2025-04-26T15:55:59.032Z</modification><creation>2019-06-06T16:14:21Z</creation></dates><accession>S-EPMC4991002</accession><cross_references><pubmed>27538496</pubmed><doi>10.1186/s13024-016-0127-y</doi></cross_references></HashMap>